Pegcetacoplan for Geographic Atrophy
How Pegcetacoplan Treats Geographic Atrophy
Geographic atrophy (GA) is the advanced stage of dry age-related macular degeneration (AMD). The retinal pigment epithelium (RPE), a layer of cells that supports your light-sensing photoreceptors, breaks down and dies in expanding patches. Over months and years, these patches destroy the central vision you rely on for reading, driving, and recognizing faces.
GA differs from wet AMD because no abnormal blood vessels grow beneath your retina. The damage comes from a slow, progressive loss of retinal cells driven by your own immune system. Peripheral vision remains intact, but the central blind spots can make everyday tasks difficult as the patches enlarge. Until 2023, no FDA-approved treatment existed for this condition.
Pegcetacoplan is a complement C3 inhibitor. Your immune system uses a chain of proteins called the complement cascade to fight infections, but in geographic atrophy this cascade becomes overactive and attacks healthy retinal cells. Pegcetacoplan blocks complement protein C3, which sits near the top of this cascade, and calms the immune-driven destruction of your RPE and photoreceptors.
According to the AAO (2023), the FDA approved pegcetacoplan on February 17, 2023, making it the first drug ever approved for geographic atrophy secondary to AMD. By targeting C3, this medication interrupts the complement cascade at an early point, reducing the inflammatory signals that cause retinal cell death.
Two phase 3 trials, OAKS and DERBY, tested pegcetacoplan in patients with geographic atrophy over 24 months. According to the AAO (2023), pegcetacoplan slowed GA lesion growth by 14 to 20 percent compared to untreated eyes. The drug does not restore vision you have already lost. It slows the rate at which the atrophic patches expand, preserving the functional vision you still have.
Both trials enrolled patients with well-defined GA lesions and tracked growth using advanced imaging. The reduction in growth rate means the atrophic patches expand less each year compared to no treatment, giving you more time with your remaining central vision.
Your retina specialist may recommend pegcetacoplan if you have geographic atrophy from dry AMD. The medication targets GA at any stage, from smaller patches to larger areas of atrophy. According to FDA prescribing information (2024), you should not receive pegcetacoplan if you have an active eye infection, active inflammation inside the eye, or a known allergy to the medication. Your doctor will evaluate your medical history, imaging, and overall eye health before starting treatment.
What Happens During Treatment
Your retina specialist delivers pegcetacoplan as an intravitreal injection, placing a small needle through the white part of your eye into the gel-filled cavity behind the lens. Before the injection, your doctor applies numbing drops and an antiseptic to your eye surface. A lid holder keeps your eye open during the procedure. The injection itself takes seconds. Most patients feel pressure but not sharp pain.
Each dose delivers 15 mg of pegcetacoplan to the back of your eye, where the medication reaches the affected retinal tissue. You can go home soon after the injection, though your vision may be blurry for a few hours.
According to FDA prescribing information (2024), your doctor can administer pegcetacoplan every 25 to 60 days, which translates to monthly or every-other-month injections. Both schedules slow GA progression. The every-other-month schedule carries a lower risk of developing wet AMD and cuts the number of office visits you need each year.
According to the AAO (2024), the every-other-month schedule is also more cost-effective than monthly dosing. Your retina specialist will recommend a schedule based on your disease severity, response to treatment, and practical considerations such as travel distance and availability.
You may notice mild redness, a gritty sensation, or slight blurriness for a day or two after the injection. These effects are common with any intravitreal injection and resolve on their own. Your doctor will check your eye pressure before you leave the office.
- Avoid rubbing your eye for the rest of the day
- Use any prescribed antibiotic eye drops as directed
- Contact your doctor if you develop increasing pain, worsening vision, or sensitivity to light
- You can resume most normal activities the next day
According to the AAO (2023), pegcetacoplan treatment is ongoing and has no set end date. GA lesion growth resumes when you stop the injections. Your retina specialist will monitor your response at each visit and adjust your schedule as needed, but plan for long-term treatment to get the most benefit from the medication. Stopping treatment is a decision you and your doctor make together, weighing the benefits of continued protection against the burden of ongoing injections.
Risks and Safety Considerations
One of the main risks of pegcetacoplan treatment is conversion to wet AMD, where abnormal blood vessels begin growing beneath your retina. According to FDA prescribing information (2024), 12 percent of patients on monthly dosing and 7 percent on every-other-month dosing developed wet AMD at 24 months, compared to 3 percent in the untreated control group. Your retina specialist will check for signs of wet AMD at every visit using OCT imaging. If conversion occurs, anti-VEGF (vascular endothelial growth factor) injections can treat the new blood vessel growth.
According to the AAO (2023), doctors have reported occlusive retinal vasculitis in some patients after pegcetacoplan injections. This rare but serious inflammation of the retinal blood vessels can occur as early as the first dose. Symptoms may include sudden vision loss, new floaters, or eye pain. Report any of these symptoms to your eye doctor the same day. Other rare injection-related complications include endophthalmitis (an eye infection) and retinal detachment, which occur with any intravitreal injection.
Contact your retina specialist or go to urgent eye care if you experience any of the following after an injection:
- Sudden decrease in vision or new blind spots
- Increasing eye pain that does not improve
- New floaters, flashes of light, or a dark shadow across your vision
- Redness that worsens instead of improving
Early treatment of these complications protects your remaining vision and prevents permanent damage.
Questions About Pegcetacoplan Injections for Geographic Atrophy
Pegcetacoplan does not restore vision that geographic atrophy has already taken. The medication slows the expansion of atrophic patches in your retina, preserving the functional vision you still have. Starting treatment earlier, when more healthy retinal tissue remains, gives you the best chance of maintaining useful vision long-term.
Your retina specialist will help you weigh both options. Every-other-month dosing requires fewer office visits and carries a lower risk of wet AMD conversion. Monthly dosing may slow lesion growth at a higher rate. Many patients start with every-other-month dosing and adjust based on their imaging results over time.
Contact your retina specialist to reschedule as soon as you can. The protection pegcetacoplan provides decreases as the medication wears off between doses. A single missed dose will not cause immediate damage, but consistent treatment produces better long-term results. Your doctor can help you get back on schedule.
Your retina specialist will evaluate your specific situation. Having wet AMD in one eye does not disqualify you from treatment in the other eye. Your doctor will weigh the elevated wet AMD conversion risk against the benefit of slowing geographic atrophy and may coordinate both treatments on the same visit schedule.
Discuss all of your current eye medications with your retina specialist. If you receive anti-VEGF injections for wet AMD in one eye and need pegcetacoplan for GA in the other, your doctor can coordinate both schedules. The two medications treat different conditions through different mechanisms and do not interfere with each other.
Your retina specialist uses optical coherence tomography (OCT) and fundus photography to measure the size of your geographic atrophy lesions over time. By comparing images from visit to visit, your doctor can track whether the growth rate has slowed compared to the expected untreated progression. You may not notice a change in your vision since the goal is to slow future loss rather than improve current sight.
Protect Your Remaining Vision
If you have geographic atrophy, talk to your retina specialist about whether pegcetacoplan may help preserve your central vision. Regular monitoring and consistent treatment give you the strongest foundation for maintaining independence and quality of life.